We were fitting a square piece into a round hole.
The new name reflects that PCOS involves multiple hormonal disruptions affecting metabolism and overall health, not just ovarian dysfunction as the old term suggested. Misclassification as an ovarian disease limited research funding to 0.1% of budgets and prevented development of targeted medications, leaving patients with off-label treatments.
- 170 million women worldwide have the condition; 70% are misdiagnosed
- Old classification limited research funding to 0.1% of budgetary allocation
- 14-year process involved 22,000 people, including 14,500 with the condition
- New name: polycystic ovarian metabolic polyendocrine syndrome
After 14 years of research, PCOS is renamed to Polycystic Ovarian Metabolic Syndrome to better reflect its systemic endocrine nature, addressing misdiagnosis affecting 170 million women globally.
After fourteen years of negotiation between physicians, researchers, and patients themselves, a condition affecting one in eight women worldwide has been given a new name. The polycystic ovary syndrome—PCOS—is now called polycystic ovarian metabolic polyendocrine syndrome, a shift that Helena Teede, president of the International Society of Endocrinology and director of the Monash Centre for Health Research and Implementation in Melbourne, describes as overdue correction of a fundamental misclassification that has shaped how 170 million women receive care.
Teede led the effort to rename a disorder whose old terminology, she explains, created cascading failures across medicine. The problem was not merely semantic. When health systems worldwide categorized PCOS as an ovarian disease, research funding followed that logic—allocating roughly 0.1 percent of budgets to a condition affecting 12 to 15 percent of women. No targeted medications were ever developed. Medical schools taught it as a single hour within gynecology courses, leaving cardiologists, psychiatrists, dermatologists, and primary care physicians unprepared to recognize or treat it. Women ended up seeing specialists trained only in ovarian procedures, when their actual condition involved disrupted hormones rippling through their entire bodies.
The new name attempts to correct this. Polyendocrine signals that multiple hormonal systems are affected—roughly eight different hormonal disruptions that vary dramatically from person to person and across a woman's lifespan. Metabolic captures the associated risks: insulin dysfunction leading to early diabetes, weight gain, heart disease (the leading cause of death among women globally), and dangerous pregnancy complications. The term still includes ovarian because the ovaries are secondarily affected by these hormonal cascades. Syndrome acknowledges the complexity.
Teede's fourteen-year process required an unusual coalition. Unlike a localized cardiac condition that cardiologists could address alone, this disorder demanded obstetricians, gynecologists, fertility specialists, endocrinologists, primary care doctors, nutritionists, psychologists, and cardiologists working in concert. Of the 22,000 people involved in developing the new framework, 14,500 were women living with the condition. This patient-centered approach shaped decisions that pure medical logic might have missed. One proposed name, EMOS, was rejected because it carries subcultural weight in Spanish and South American contexts, associated with punk and gothic movements. The term reproductive, though medically accurate, was excluded because in many parts of the world, labeling women with reproductive health problems can damage their social standing when fertility is tied to worth—even though the condition is treatable and does not prevent desired family size.
The current treatment landscape reflects decades of underfunding. Patients receive medications developed for other diseases: birth control pills to modulate hormonal imbalance, metformin (a diabetes drug) to address insulin resistance, anti-androgens, and fertility hormones. These work, but not optimally. Targeted therapies never materialized because research money never arrived.
Teede emphasizes that lifestyle intervention, while important, cannot be the primary answer when one in 1,500 people with significant obesity achieve sustained weight loss through behavior change alone. Blaming patients for weight gain when their bodies have higher insulin resistance and metabolic dysfunction is, she argues, profoundly unjust. Governments must improve food systems, reduce ultra-processed foods, and make healthy eating affordable—as Spain and cities like Barcelona have begun to do. Without systemic support, telling people to eat less and exercise more amounts to moral judgment masquerading as medicine.
The underdiagnosis remains severe. Roughly 70 percent of women do not receive a diagnosis until they attempt pregnancy, by which point fertility complications have often already begun. Early diagnosis with proper systemic treatment prevents these cascades. Women can achieve the family size they desire, avoid late pregnancies, and sidestep the complications that now devastate so many. The renamed syndrome is a beginning—a signal that the entire system, not just the label, requires repair.
Citas Notables
The name was incorrect and didn't reflect what the problem actually was—a disruption of our endocrine or hormonal system. Those affected know they don't have an ovarian syndrome. They know their symptoms are broader, but they've been placed in the wrong category and received inadequate care for too long.— Helena Teede, president of the International Society of Endocrinology
We can't use lifestyle intervention to make people feel guilty. We can't use it without offering systemic and policy support. And we can't suggest it will be a miracle cure for people with significant obesity—medical or surgical therapy is the only way to make a difference now.— Helena Teede
La Conversación del Hearth Otra perspectiva de la historia
Why did it take fourteen years to change a name?
Because this wasn't just about words. You needed obstetrics, gynecology, endocrinology, cardiology, primary care—all these fields that don't normally talk to each other. And you needed the women living with it to have real power in the room, not just be consulted. That takes time.
What happens now that the name has changed?
The hard part begins. The name change opens the door, but you still need to reclassify it in health systems, fund research properly, retrain medical schools, and change how doctors think about it. The name alone doesn't fix anything.
You mentioned 70 percent misdiagnosis. How does that happen?
Because doctors are looking for an ovarian problem when the real issue is hormonal chaos affecting the whole body. A woman goes to her gynecologist, gets told her ovaries look fine, and leaves thinking she's fine—even though her insulin is dysregulated and her heart risk is climbing.
The lifestyle conversation seemed important to you.
It's the thing that infuriates me most. We tell women to eat less and exercise more, as if their bodies are just like everyone else's. But their insulin resistance makes weight loss biochemically harder. Then when they can't lose weight, we blame them. We'd never accept a treatment that works for one in 1,500 people, but we demand that of women.
What about the countries where reproductive health carries social stigma?
If you label a woman with a reproductive disorder in a place where her fertility determines her value, you've just harmed her socially—even though the condition is treatable and doesn't prevent pregnancy. That's why we excluded that term, even though it's medically correct.
What does early diagnosis actually change?
Everything. If you catch it before pregnancy attempts, you can prevent the complications. You can treat the hormonal imbalance. Women get the family size they want, without the late pregnancies and the medical crises. Right now, most women don't find out until it's already complicated their fertility.